My research focuses on the discovery and development of novel therapies for colorectal cancer interception and investigating epigenetic pathways implicated in the early stages of the disease. As PI or co-Investigator on several NIH-funded grants, I laid the groundwork in identifying novel epigenetic mechanisms of dietary compounds that affect Wnt/?-catenin and DNA repair.
I also have extensive Pharma R&D expertise in developing novel anticancer drugs through close collaboration with R&D teams. As the Director of Antibody and Biopharmaceuticals Core (ABC), I support and advance the development of monoclonal antibodies.